Contineum Therapeutics News

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific

BusinesswireJun 5 04:05

Express News | Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

BreakingsJun 4 04:05

Contineum Therapeutics Sets Executive Severance Plan

TipRanksJun 1 06:00

Stifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

TipRanksMay 21 10:05

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific

BusinesswireMay 21 04:05

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy From RBC Capital

TipRanksMay 17 18:27

Contineum Therapeutics (CTNM.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -3.55 dollars, previous value of -2.12 dollars.

Contineum Therapeutics (CTNM.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -3.55 dollars, previous value of -2.12 dollars.

Zhitong FinanceMay 17 06:20

Contineum Therapeutics | 10-Q: Quarterly report

SEC announcementMay 17 05:04 · Announcements

Contineum Therapeutics 1Q Loss/Shr $3.55 >CTNM

Contineum Therapeutics 1Q Loss/Shr $3.55 >CTNM

Dow JonesMay 17 04:06

Press Release: Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights -Contineum is focused on leading the Neuroscience, Inflammation and Immunology (NI&I) field- -Succe

Dow JonesMay 17 04:05

Stifel, Morgan Stanley Bullish on Newly Public Contineum

Seeking AlphaMay 1 01:10

Contineum Therapeutics Price Target Announced at $29.00/Share by Stifel

Contineum Therapeutics Price Target Announced at $29.00/Share by Stifel

Dow JonesApr 30 17:30

Contineum Therapeutics Initiated at Overweight by Morgan Stanley

Contineum Therapeutics Initiated at Overweight by Morgan Stanley

Dow JonesApr 30 17:25

Contineum Therapeutics (CTNM.US) was first covered by Stifel, giving it a buy rating, with a target price of $29.00.

Contineum Therapeutics (CTNM.US) was first covered by Stifel, giving it a buy rating, with a target price of $29.00.

Zhitong FinanceApr 30 17:20

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

Morgan Stanley analyst Jeffrey Hung initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and announces Price Target of $25.

BenzingaApr 30 17:15

Contineum Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 58.83% Morgan Stanley → $25 Initiates Coverage On → Overweight

BenzingaApr 30 17:13

Contineum Therapeutics: A Strategic Buy Amidst Promising Clinical Trials and Strong Revenue Projections

TipRanksApr 30 16:55

Buy Rating Justified by Contineum Therapeutics' Diverse Pipeline and IPF Program Potential

TipRanksApr 30 16:55

NASDAQ New 52-Week Highs And Lows

New Highs 26 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Blue World Acqn Cl A BWAQ 11.27 211,893 C

Dow JonesApr 18 03:21

UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following bette

BenzingaApr 16 22:15